About Sigma intracellular receptor 2
Sigma intracellular receptor 2 (TMEM97) is a protein
from Homo sapiens identified by UniProt accession
Q5BJF2, 176 residues long.
MolForge cross-references it against 0 known binders and
204 disease associations.
Target properties
| Protein name | Sigma intracellular receptor 2 |
| UniProt accession | Q5BJF2 |
| Gene | TMEM97 |
| Organism | Homo sapiens |
| Length | 176 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (204)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.19
- sporadic amyotrophic lateral sclerosis · score 0.16
- serine/threonine-protein kinase 17B measurement · score 0.16
- OCIA domain-containing protein 1 measurement · score 0.16
- macrophage scavenger receptor types I and II measurement · score 0.16
- Abelson tyrosine-protein kinase 2 measurement · score 0.16
- breast cancer anti-estrogen resistance protein 3 measurement · score 0.16
- non-receptor tyrosine-protein kinase TYK2 measurement · score 0.16
- apolipoprotein A 1 measurement · score 0.15
- high density lipoprotein cholesterol measurement · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5BJF2-F1 | alphafold | PREDICTED | 90.17 | — |
Amino-acid sequence (176 residues)
MGAPATRRCV EWLLGLYFLS HIPITLFMDL QAVLPRELYP VEFRNLLKWY AKEFKDPLLQ EPPAWFKSFL FCELVFQLPF FPIATYAFLK GSCKWIRTPA IIYSVHTMTT LIPILSTFLF EDFSKASGFK GQRPETLHER LTLVSVYAPY LLIPFILLIF MLRSPYYKYE EKRKKK
Explore Sigma intracellular receptor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets